
TSE:SIS
This summary was created by AI, based on 6 opinions in the last 12 months.
Savaria Corp (SIS-T) is gaining positive traction among analysts due to its resilience in the face of tariff challenges, notably pivoting its focus towards the European market while establishing production facilities in the U.S. The company's growth potential is fueled by the aging population's desire to remain at home, presenting a solid case for its accessibility products, which are primarily FDA-regulated and often exempt from tariffs. Analysts highlight a strategic approach, recommending a phased purchasing strategy to capitalize on price movements. With a current yield of 2.69% and a targeted price of $24.44, Savaria is seen as a long-term hold in the accessibility sector, benefiting from cost-cutting measures and ongoing product introductions.
Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The Handicare acquisition is very big and will increase revenues by 50%. 5i likes the deal and believes there will be additional synergie over time. The deal is set to increase geographic reach and customer base. The financing may cause short term volatility but EBITDA was better than expected and sales were just below estimates. Unlock Premium - Try 5i Free